Document is current

Article History

Received: 1 October 2024

Accepted: 26 November 2024

First Online: 4 February 2025

Declarations

:

: This study has been approved by the North-East Newcastle and North Tyneside 2 Research Ethics Committee and the Health Research Authority (20/NE/0127). Due to its retrospective nature, written consent to take part in this study was waived. All patients provided written consent to undergo the ICP monitoring procedure as part of their standard clinical care.

: Not applicable.

: LD is supported by an Academic Clinical Fellowship from the National Institute for Health Research and was the recipient of a research fellowship sponsored by B.Braun. LDW has received honoraria from and served on advisory boards for Medtronic, B.Braun and Codman. AKT research time was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. MSM serves on the advisory board for AbbVie, Pfizer, Eli Lilly, Lundbeck and TEVA and has received payment for the development of educational presentations from AbbVie, Eli Lilly, Lundbeck and TEVA. SC, DM and FB report no disclosures.